Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs were updated on Oct. 1, 2025 and will take effect on Nov. 1, 2025:
Prescription Drug Policies
- Bempedoic Acid
- Brensocatib
- Camzyos
- Cholestasis Pruritus
- Constipation Agents
- Fabhalta
- Gattex
- Hepatitis C Direct Acting Antivirals
- Isturisa
- Neurotrophic Keratitis
- PCSK9 Inhibitors
- Peginterferon
- Primary Biliary Cholangitis
- Statin
- Tryvio
- Vascepa
- Verquvo
- Wakix
- Zelsuvmi
- Zilbrysq
To view prescription drug policies specific to a formulary or medication list, please select that formulary on the Prior Authorization page of our website.
Medical Pharmacy Solutions Program Policies
- ACTH
- Adcetris
- Berinert
- Blincyto
- Cinryze
- Darzalex IV
- Datroway
- Elrexfio
- Erbitux
- Evkeeza
- Firazyr
- Gamifant
- Haegarda
- IVIG
- Kalbitor
- Leqvio
- Lynozyfic
- Monjuvi
- Rituximab_IV
- Ruconest
- Rybrevant
- SCIG
- Synagis
- Takhzyro
- Tepezza
- Ustekinumab
- Vectibix
To access Medical Pharmacy Solutions policies, please visit the Medical Pharmacy Policies (GatewayPA) page.
For additional questions, please refer to the Prior Authorization section of our website or contact your BCBSKS provider relations representative.